Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

28.50USD
26 May 2017
Change (% chg)

$-0.21 (-0.73%)
Prev Close
$28.71
Open
$28.70
Day's High
$28.71
Day's Low
$28.25
Volume
1,034,013
Avg. Vol
1,982,034
52-wk High
$56.44
52-wk Low
$28.07

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $31,698.78
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 4.35

Financials

  TEVA.N Industry Sector
P/E (TTM): 201.91 29.41 30.38
EPS (TTM): 0.15 -- --
ROI: 0.53 13.85 13.36
ROE: 0.24 14.79 14.50

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

22 May 2017

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

22 May 2017

UPDATE 2-Celgene MS drug clears key trial, but disability data falls short

May 22 Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

22 May 2017

UPDATE 1-Teva Pharmaceutical's search committee recommends foreign CEO -report

TEL AVIV, May 18 Teva Pharmaceutical Industries' search for a new chief executive has resulted in the selection of a foreigner as the leading candidate, Israeli financial news website Calcalist said on Thursday.

18 May 2017

Teva Pharm search committee recommends foreigner for CEO -report

TEL AVIV, May 18 Teva Pharmaceutical Industries' search for a new chief executive has resulted in the selection of a foreigner as the leading candidate, Israeli financial news website Calcalist said on Thursday.

18 May 2017

BRIEF- Sosei Group unit Heptares to receive $5 million milestone

* Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist, discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd has triggered a $5 million payment from Teva to Heptares under the terms of their licensing and drug-discovery agreement signed in 2015

18 May 2017

BRIEF-Teva Takeda Pharma to up overseas production of generic medication to cut costs - Nikkei

* Teva takeda pharma to increase overseas production of generic medication to cut costs per year as drug prices continue to decline - Nikkei Source text (http://s.nikkei.com/2qOMEN4) Further company coverage:

17 May 2017

BRIEF-Teva announces launch of generic Glumetza in the U.S.

* Teva announces launch of generic Glumetza® in the United States

15 May 2017

BRIEF-Otsuka, Teva sign licensing agreement for Japan on TEV-48125

* Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125)

15 May 2017

UPDATE 2-Teva Q1 profit tops estimates, revenue up on Actavis deal

* Increases Actavis synergy, cost benefit estimate by $200 mln

11 May 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF78.50 -0.10
Biogen Inc (BIIB.OQ) $250.80 -2.17

Earnings vs. Estimates